AELIUS BIOTECH LIMITEDActive
Key figures
Like most small UK companies, AELIUS BIOTECH LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.
Balance sheet structure
Filed accounts2020/21–2025
| 2020/21 | 2021/22 | 2023 | 2025 | |
|---|---|---|---|---|
| Cash at bank and in hand | 100,208 | 63,709 | — | 321,513 |
| Total assets | 110,001 | 107,645 | 1,338,233 | — |
| Total liabilities | — | — | 41,670 | — |
| Net assets / total equity | 62,055 | 66,403 | 1,296,563 | 236,499 |
| Average number of employees | 0 | 1 | 4 | 16 |
A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.
Principal activity
Accounts 2025The principal activity of the company during the financial year was developing world leading in vitro models of the gastrointestinal tract and offering them as a commercial service to drive and de-risk research and develop for customers.
As described in the company's latest filed accounts.
Summary: AELIUS BIOTECH LIMITED
Company
AELIUS BIOTECH LIMITED is a private limited company registered with Companies House under company number 11535653. It was incorporated on 24 Aug 2018. Its status is active. The registered office is in Newcastle upon tyne (NE1). Its nature of business (SIC 2007) is other research and experimental development on natural sciences and engineering (72190), other human health activities (86900).
Accounts
The latest accounts in the database are for 2025 (period ending 31 Dec 2025); the company files small company accounts (filleted). Net assets were £236,499, down 81.8% on the previous year. Cash at bank and in hand was £321,513. The company had an average of 16 employees. Figures are available for 4 financial years (2020/21–2025).
Control and charges
One person with significant control is registered. 2 of 2 registered charges are outstanding.
Filing deadlines
The next accounts are due by 30 Sep 2027. The next confirmation statement is due by 15 Jun 2027.